Google Secures Pentagon AI Deal for Classified Projects 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
HOUSTON, April 26, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3 at 2:10 p.m. EDT in Boston, Massachusetts.
A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors: Bellicum Pharmaceuticals Alan Musso, CFO 832-384-1116 [email protected] Media: BMC Communications Brad Miles 646-513-3125 [email protected]
